Immunological screening with the anti-p53 moAb, PAb1801 of a cDNA expression library, prepared from human B lymphoma cells, led us to identify a new human 205 kDa protein called RB18A for`Recognized By PAb1801 moAntibody'. Immunoblotting or immunoprecipitation of fusion protein or in vitro translated protein, respectively, demonstrated that RB18A protein was recognized by several anti-p53 moAb reacting with the N or C-terminal domains of p53. Full length sequence of RB18A cDNA and computer analysis demonstrated that despite common antigenic determinants between RB18A and p53 proteins, nucleotide and deduced protein sequences did not reveal any signi®cant homologies. RB18A mRNA was detected in all tissues tested except in kidney. In addition, RB18A protein shared identical functions with p53 protein: binding to DNA or to p53 and self-oligomerization. Furthermore, RB18A regulated p53 speci®c binding on his DNA consensus binding site. These functions were associated to the C-terminal domain of RB18A protein and more speci®cally to the PAb421 binding site present in this domain. The activation by RB18A of p53 binding on DNA was induced through an unstable interaction between both proteins. Altogether, our data demonstrated that RB18A protein shares antigenic and functional properties with p53 and regulated p53 functions.
Introduction
The p53 protein plays an important and complex role in cells. In normal cells, wild-type p53 is involved in genome stability and in reparation of DNA lesions (Kastan et al., 1991; Kastan et al., 1992; Fritsche et al., 1993) . In tumor cells, overexpression of wild-type p53 induces, depending on cell type, a G1 cell-cycle growth arrest (Ginsberg et al., 1991; Mercer et al., 1991) or apoptosis in vitro (Yonish-Rouache et al., 1991; Johnson et al., 1993) and in vivo (Shaw et al., 1992; Radinsky et al., 1994) . These functions of p53 are related to its property to transactivate (Kastan et al., 1992; Scharer and Iggo, 1992; El-Deiry et al., 1993) or to repress transcription of dierent genes (Ginsberg et al., 1991; Santhanam et al., 1991; Subler et al., 1992) and to inhibit cellular DNA replication (Miller et al., 1995; Cox et al., 1995) .
The regulatory functions of p53 are associated to speci®c domains (Soussi et al., 1990) . Its N-terminal domain acts as a trans-activation domain (Fields and Jang, 1990; O'Rourke et al., 1990; Raycroft et al., 1990) . Its central domain contains a sequence-speci®c DNA binding site (Wang et al., 1993; Pavletich et al., 1993; Bargonetti et al., 1993) , which interacts with two copies of the 10 bp sequence 5'-PuPuPuC(A/T)(T/ A)GPyPyPy-3', separated by up to 13 bp (El-Deiry et al., 1992; Funk et al., 1992) . This DNA element is present in promotor of several genes including WAF1 (El-Deiry et al., 1993) , GADD45 (Kastan et al., 1992) , the muscle creatine kinase gene (Weintraub et al., 1991) , and the MDM2 gene (Barak et al., 1993) . Other domains modulate the speci®c interaction of p53 with DNA. Indeed, a tetramerization domain localized within the C-terminal stabilizes this interaction (ElDeiry et al., 1992; Funk et al., 1992; Arrowsmith and Morin, 1996) . In addition, the p53 C-terminal domain contains a negative autoregulation site of sequencespeci®c DNA binding (Hupp et al., 1992) . The Cterminal domain also carries a nonspeci®c DNA binding activity (Wang et al., 1993) . This property has been associated to a DNA annealing and strandtransfer activities of p53 (Reed et al., 1995) .
Thus, proteins which interact with one of these p53 domains should regulate p53 functions. Dierent proteins have been described as interacting with p53: viral SV40 large T antigen (Lane and Crawford, 1979) , adenovirus E1B 55K (Sarnow et al., 1982) , EBV BZLFI (Zhang et al., 1994) , cellular Hsp70 (Pinhasi-Kimhi, 1986 ), MDM2 , TBP (Seto et al., 1992) , WT1 (Maheswaran et al., 1993) , the Epstein-Barr virus/C3d receptor (CR2, CD21) (Barel et al., 1989) and more recently PACT (Simons et al., 1997) . Furthermore, monoclonal antibodies (moAb) directed against speci®c p53 domains are also p53 binding proteins which allow to analyse the role of p53 domains and to distinguish between wild-type or mutant p53 forms. PAb1620 moAb speci®cally recognized a conformational epitope only expressed on wild-type p53 (Milner et al., 1987) , while PAb240 moAb recognized a sequential epitope localized in the central region of p53 and demasked only on mutated p53 (Gannon et al., 1990) . Other anti-p53 moAb as PAb1801 (aa 46 to 55) and DO1 (aa 21 to 25) or PAb421 (aa 371 to 380) were found to be directed against either the N or the C terminal domains of the p53 protein, respectively (Legros et al., 1994) . PAb421 moAb activates the sequence-speci®c DNA binding activity of p53, in a similar manner to phosphorylation or binding of bacterial Hsp70 (dnaK) on the p53 Cterminal domain (Hupp et al., 1992) .
In the present report, screening of a cDNA library expression, prepared from human B lymphoma cells, with the anti-p53 PAb1801 moAb, led us to identify a new cellular protein, characterized by an apparent molecular weight of 205 kDa. This protein was called RB18A, as`Recognized By PAb1801 moAb'. Although no signi®cant homology has been found with p53 at the level of the nucleotide or deduced-protein sequence, RB18A protein shared some antigenic epitopes with p53 as recognized by dierent anti-p53 moAbs. Furthermore, RB18A protein carried some identical properties with the p53 protein, i.e. DNA-binding, homo-oligomerization, binding to p53 and activation of the sequence speci®c DNA binding function of p53.
Results

Isolation of clones recognized by anti-p53 moAbs
A UniZAP-XR cDNA expression library was prepared from polyadenylated RNA extracted from Raji human B lymphoma cells and was screened (6.10 5 plaque-forming units) with PAb1801, an anti-p53 moAb which speci®cally recognized the N-terminal domain of p53 (aa 46 to 55) (Legros et al., 1994) . Sixteen positive phages were isolated and inserts were excised in vivo in pBluescript vector. Then, b-galactosidase fusion proteins were produced in E. coli and immunoblotted with two anti-p53 moAbs, PAb1801 and PAb421, this latter reacting with the C-terminal domain of p53 (aa 371 to 380) (Legros et al., 1994) . Nine clones producing fusion proteins recognized by these two anti-p53 moAbs were isolated. Among these clones, eight expressed the expected p53 molecule, as con®rmed by partial cDNA sequencing (data not shown), and are represented by D22 clone (Figure 1a1 ). However, the ninth clone (D9) expressed a fusion protein characterized by an apparent molecular weight of 130 kDa (Figure 1a2 ). D9 protein antigenicity towards anti-p53 Ab was also analysed in immunoblotting or immunoprecipitation assays, on fusion protein or in vitro translated protein, respectively. D9 fusion protein was recognized by PAb1801 and PAb421 moAb (Figure 1a2 ), while in vitro translated D9 protein (Figure 1b1 ) was recognized by PAb1801, DO-1, another anti-p53 moAb and anti-p53.1, a polyclonal anti-p53 peptide antibody prepared in our laboratory (against amino acid sequence 13 to 27 of p53) but not by PAb421. Other anti-p53 moAb HO15-4, HO3-5, HO7-1, which recognized the p53 central region did not react with D9 clone product, in any assay. Thus, the protein encoded by the D9 cDNA presented common antigenic determinants with the N and C-terminal domains of p53.
Analysis of RB18A cDNA
We therefore determined the sequence of D9 cDNA. As this clone appeared to correspond to an incomplete open reading frame (Figure 2a) , a 800-base pair probe derived from the 5' end of this cDNA was generated and used in Northern blot on mRNA of various human tissues (Figure 2b) . A 8.5 kb mRNA was detected in all tissues tested except in kidney. As the highest expression was in heart, we screened a lgt11 cDNA library from the human heart with the same probe used in Northern blot studies. Three clones (9.6, 9.10 and 9.1) overlapping with D9 were obtained ( Figure 2a ). Sequence analysis of these cDNA clones identi®ed a predicted open reading frame of 1566 amino acids (Figure 3 ). An ATG codon was located 235 nucleotides downstream of the 5' end and was preceded by two in-frame stop codons. This ATG is probably the methionine initiation codon, since sequences immediately¯anking this codon contain homology to the translation initiation sequence consensus (Kozak, 1984) . A 3'-untranslated region of 877 nucleotide residues is present, but it may not contain the entire 3'-untranslated region since the polyadenylation signal is not present.
The protein encoded by this full length cDNA was named RB18A for Recognition By PAb1801 Antibody. Analysis of the amino acid sequence showed that RB18A protein contained 23.8% residues with hydroxl side chain (17.7% serine and 6.1% threonine) and was highly charged with 13.7% basic and 17.8% acidic residues. This data also allowed to predict a 166 kDa molecular weight of RB18A protein core. However, analysis of the expression of RB18A protein in Raji cells using polyclonal antibody raised against the GST-RB18A fusion protein detected a protein with an apparent molecular weight of 205 kDa and not the p53 protein (Figure 4) . The dierence between the predicted and the SDS ± PAGE-determined molecular weight is more likely due to high glycosylation and phosphorylation sites present in the protein core. Indeed, searches for structural motifs using the Prosite program revealed 13 potential N-glycosylation sites and a high number of putative phosphorylation sites (5 cAMP-and cGMP-dependent protein kinase, 29 protein Kinase C and 24 casein kinase II consensus sites). In addition, seven sequences containing the 4 aa motif Lys-Arg/Lys-X-Arg/Lys which represents the minimal nuclear localisation signal (NLS) consensus sequence could be identi®ed (Figure 3, underlined) . However, despite common antigenic determinants with p53, analysis of nucleotide and protein sequences in Genbank and EMBL databases did not reveal any signi®cant homology between RB18A and p53 proteins. Interestingly, while RB18A cDNA sequence was not present in any available data bank, a region of 244 bp (corresponding to nucleotides 2054 to 2297) presented a high sequence homology with the partial sequence of Trip2 cDNA (Lee et al., 1995) . Full length sequence of Trip2 cDNA, which is not yet available, will allow to establish the exact relationship between RB18A and Trip2 proteins.
Binding properties of RB18A protein
The presence of common antigenic determinants between RB18A and p53 proteins, despite the absence of signi®cant sequence homology in their primary structure, led us to analyse whether RB18A protein presented identical functions to p53 protein. Thus, properties of RB18A to bind to DNA, to homooligomerize and to interact with other proteins were anlaysed. These studies were performed with the translated product of D9 cDNA clone. Indeed, this latter which represents part of the full length RB18A cDNA was recognized by the dierent anti-p53 moAb mentioned above, therefore carrying the antigenic epitopes common with p53. First, DNA binding property of RB18A was analysed by measuring binding of in vitro
35
Stranslated product on DNA-cellulose, as used for DNA-binding anity of wild-type and mutant p53 (Kern et al., 1991) . In these assays, in vitro 35 Stranslated product of wild-type p53 and luciferase were used as positive and negative control, respectively. In presence of the predetermined optimal 100 mM NaCl concentration (Figure 5a ), a similar yield (20% of input), of added RB18A or wild-type p53 proteins was retained on double-stranded DNA-cellulose ( Figure  5b ), as well as wild-type p53 protein.
In control, luciferase product did not bind to DNAcellulose (less than 0.1% of input). Similar results were obtained using single-stranded DNA-cellulose (data not shown). The interaction of in vitro translated RB18A product with DNA-cellulose was not mediated by a component of reticulocyte lysate, as identical interaction was observed with RB18A fusion protein (see Figure 7 , part D). Thus, RB18A protein is a DNA binding protein, as well as p53 protein.
Second, formation of RB18A homo-oligomers was also investigated by incubating in vitro translated product of RB18A with RB18A inserted into the pGEX-4T-3 bacterial expression vector (GST-RB18A-N1). Luciferase translated products and GST were also used in control. As shown in Figure 6 , 35 S-RB18A protein bound on GST-RB18A-N1, 10% of input (lane 2) but not on GST (lane 3). In control, luciferase did not bind either on GST-RB18A-N1 (lane 5) or on GST (lane 6). Thus, RB18A protein has also the property to self-oligomerize.
Third, binding properties of RB18A protein to wildtype p53 and mutant p53 273P proteins were analysed. As shown in Figure 6 , both wild type p53 (lane 8) and mutant p53 (lane 11) bound, with an identical yield of clone, which allowed to isolate the full length RB18A cDNA, was obtained after immunoscreening with the PAb1801 anti-p53 moAb of a Uni-Zap XR cDNA expression library made from Raji cell mRNA. A 800-base pair probe derived from the 5' end of this cDNA was used to screen a human heart cDNA library to obtain the 5' end of RB18A cDNA. Three additional clones were obtained (clones 9.6, 9.10 and 9.1). They overlapped in their 3' region with the 5' part of D9 clone. The coding region is indicated as an open box, while the untranslated regions are shown as solid lines. Some of the restriction sites are indicated, B: BamHI, E: EcoRI, N: NheI, P: PstI. (b) Northern analysis of dierent tissues. A blot containing 5 mg polyadenylated RNA from a variety of human tissues (as described in Materials and methods) was screened either with the 800-base pair probe derived from the 5' end of the D9 partial RB18A cDNA (upper panel) or with a human b actine probe, with two forms of 2 and 1.8 kb in heart and skeleton muscle, as expected (lower panel) 10% of input, on GST/RB18A and not on GST (lanes 9 and 12), respectively. Quanti®cation of the amount of RB18A or p53 proteins retained on GST-RB18A supported a molar ratio of one to one in both cases. Thus, RB18A protein presented the property to bind to wild-type, as well as to mutant p53.
Mapping of binding domains of RB18A protein
The domains of RB18A responsible for its binding activities were analysed using deletion mutants of GST fusion proteins of RB18A ( Figure 7a ) and by immunoblotting assays with PAb1801 and PAb421 S-translated products of RB18A and p53wt cDNAs. Both p53 binding and homo-oligomerization domains were localized on the same region (between amino acids 1234 and 1406) (Figure 7c) .
DNA-binding domains were determined by incubating the dierent GST-fusion proteins with DNAcellulose and by detecting bound proteins by immunoblotting with polyclonal anti-GST Ab. As shown in Figure 7d , binding of RB18A on DNA required a domain also characterized by amino acids 927 to 1406. All the results obtained are summarized in Figure 7e .
RB18A regulates the sequence-speci®c DNA binding function of p53
Binding property of RB18A on p53 led us to analyse whether RB18A could regulate p53 speci®c binding on his DNA consensus binding site (Funk et al., 1992) . For this purpose we used the electrophoretic mobility shift assay (EMSA) (Figure 8 , Part A), as described by Wolkowicz et al., (1995) . This assay allowed us to demonstrate that in vitro translated product of wild type p53, bound speci®cally to DNA only when activated by PAb421 (lane 5) but not in non activated Figure 3 Nucleotide and deduced amino acid sequences of RB18A cDNA. The amino acid sequence is shown in one-letter code. The putative NLS are underlined state (lane 2) or when incubated with PAb1801 (lane 6). In these conditions, while C-terminal GST-RB18A fusion protein (GST-RB18A-N2) did not interact directly with the speci®c p53 oligonucelotide (lane 4), its addition induced the binding of p53 to its speci®c oligonucleotide (lane 7). Identical results were obtained using GST-RB18A-NC2 (data not shown). The speci®city of this binding was supported by its inhibition in presence of 50-fold molar excess of unlabeled p53 speci®c oligonucleotide (lane 8) and not by a non speci®c oligonucleotide (lane 9). Activation of p53 DNA binding activity by RB18A was not detected when the GST-RB18A-NI1 mutant, deleted in its p53-binding domain, was used instead of the GST-RB18A-N2 fusion protein (lane 10), suggesting that this activation needed the interaction of both proteins.
Analysis of the components present in the speci®c DNA-binding complex was performed using either anti-p53 moAbs, polyclonal anti-GST Ab or anti-RB18A Ab. As shown in Figure 8, Eect of salt concentration on double-stranded DNA-binding ability of RB18A. Five ml of in vitro translated product of RB18A cDNA was incubated with DNA-cellulose at the indicated concentration of NaCl (mM) as described in Materials and methods. Proteins were analysed on a 10% SDS ± PAGE. Bound proteins were quanti®ed by laser densitometry of the autoradiogram. (b) DNA-binding assay in presence of 100 mM NaCl using 5 ml of rabbit reticulocyte lysate programmed by RB18A, p53wt, or Luciferase cDNAs (Figure 9 ), in a dose-dependent manner, whether added before (lanes 6 to 8) or after (lanes 1 to 4) the Moab. In control, the RB18A mutant which lost its binding domain with p53 did not have the same eect (lanes 5 or 9). Altogether, these data supported that RB18A activated p53 DNA-binding activity, while not present in the observed complex.
Discussion
We herein report the molecular cloning of a new human protein identi®ed in the human B lymphoma cell line Raji, by its common antigenic determinants with the p53 protein and characterized by an apparent molecular weight of 205 kDa. This protein was called RB18A for`Recognized By PAb1801 Antibody', as isolated after immunological screening of a cDNA expression library using the speci®c anti-p53 moAb, PAb1801. Presence on RB18A protein of common antigenic determinants with the p53 protein was demonstrated as b-galactosidase-RB18A fusion proteins or in vitro translated products of RB18A cDNA were recognized by speci®c anti-p53 antibodies. This cross-reactivity was supported by binding on RB18A of anti-p53 moAb which reacted with three distinct domains of p53. Indeed, the epitopes recognized on p53 by antip53 moAb as DO-1, PAb1801 and PAb421 are localized in its N or C terminal domains and are de®ned by aa sequence 21 ± 25, 46 ± 55 and 371 ± 380, respectively (Legros et al., 1994) . PAb1801, DO-1 moAb and a polyclonal anti-p53.1 Ab, prepared against the p53 N-terminal amino acid sequence 13 ± 27, recognized the native RB18A protein. PAb421, directed against the p53 C-terminal domain, recognized only the SDS-treated form of RB18A protein. Absence of PAb421 interaction with native RB18A could be due to the masking of the PAb421 epitope in the protein core. It was also demonstrated that in vitro phosphorylation on PAb421 moAb epitope of murine (Milne et al., 1996) or human (Takenaka et al., 1995) p53 could occur in reticulocyte lysates and that these phosphorylations inhibited PAb421 moAb interaction with p53. This cross-reactivity was limited to the p53 N and C domains, as anti-p53 moAb reacting with the central domain of p53, as HO15-4, HO3-5, HO7-1, did not react with RB18A protein.
However, computer analysis of amino acid sequence (deduced from cDNA data) of the primary structure of both proteins did not allow to localize any signi®cant identity or homology between both RB18A and p53 protein sequences. This apparent discrepancy was more likely due to the presence on RB18A of epitopes common with p53 and expressed on the tertiary structure of native RB18A protein, also partially conserved in SDS-treated RB18A protein. Similar data were obtained by Stephen et al. (1995) who reported that moAbs, including antip53 moAb, with known peptide reactivity, selected from 12-mer and 20-mer phage-displayed libraries not only the expected peptides but also sequences with no discernible homology with the original antigen. Presence of epitopes de®ned as common antigenic determinants and characterized by no primary sequence homology has been previously mentioned and called`mimotopes' by Geysen et al., 1986 Geysen et al., , 1987 . Interaction of a speci®c moAb with both epitope and mimotope motifs was explained by interaction with the two dierent ligands either of distinct paratopes on the same moAb or alternative contacts of the same paratope (Stephen et al., 1995) . Furthermore, anti-p53 PAb421 moAb was also shown to react with a mouse protein which was homologous to the yeast RAD50 protein, previously identi®ed as a T-Agbinding protein (Daud et al., 1993) .
In addition, RB18A protein shared some identical properties with p53 protein: indeed, RB18A protein binds to DNA, self-oligomerize and binds to p53. This was also supported by co-immunoprecipitation of p53 and RB18A on polyclonal anti-RB18A antibody (data not shown). In addition, RB18A is able to activate the sequence speci®c binding of p53 to DNA. All these activities, which supported the functional homology between RB18A and p53 proteins, were associated to the C-terminal domain of RB18A protein, as for p53, and more speci®cally to the PAb421 binding site present in this domain. Indeed: (a) the domain responsible for DNA binding activity and localized on aa 927 ± 1406, was recognized by PAb421 moAb. Part of this domain is also responsible for the selfoligomerization of RB18A (aa 1234 ± 1406); (b) in opposite to the full length RB18A, deletion of the regions recognized by PAb421 moAb abolished RB18A activation of the p53 speci®c DNA binding activity; (c) PAb421 also de®ned in p53 a motif able to activate the sequence speci®c binding of p53 to DNA. Jayaraman and showed that the C-terminus of human p53 (aa 311 ± 393) was able to activate in trans the latent activity of sequence speci®c DNA binding activity of p53. A polypeptide corresponding to the p53 amino acid sequence 311 to 367 did not induce this activation suggesting that the 26 C-terminus residues were crucial for this activity. This result was con®rmed by Hupp et al. (1995) who found that small peptides carrying the PAb421 epitope also stimulated the DNAbinding activity of p53.
The possibility that PAb421 moAb may de®ne a domain which bound to DNA and/or was responsible for oligomerization has been suggested by Daud et al. (1993) and Kim et al. (1996) . Indeed, PAb421 moAb cross-reacted with the mouse RAD50 protein, homologous to the yeast RAD50 protein (Daud et al., 1993) , whose expression was increased in response to DNA damage. RAD50 protein carries DNA-binding oligomerization (Daud et al., 1993 ; Raymond and Kleckner, S-translated products of RB18A, luciferase, p53wt and mutated p53. One mg of GST-RB18A (lanes 2, 5, 8, and 11) or GST alone (lanes 3, 6, 9, and 12) were incubated with 5 ml of rabbit reticulocyte lysate programmed by RB18A (lanes 2 and 3) , luciferase (lanes 5 and 6), p53wt (lanes 8 and 9) and mutated p53 (lanes 11 and 12) cDNAs. In control, 10% of the dierent proteins (lanes 1, 4, 7 and 10) used in each in vitro binding assay were directly run in gel 5) and GST (lanes 6) with PAb1801 (b1) or PAb421 (b2) moAbs and anti-GST Ab (b3). Position of molecular marker size is indicated on the right part of the gel. (c) Mapping of the domains involved in oligomerization and interaction with p53. Deletion mutants of RB18A (lanes 1 to 5) or GST (lane 6) were incubated with 5 ml of rabbit reticulocyte lysate programmed by RB18A (c1) or p53-H8 (c2) cDNAs. Bound proteins were eluted and run on a 7.5% (c1) or 10% (c2) SDS ± PAGE. In control, standards representing 10% of each added protein were used (lane S). (d) Mapping of the DNA-binding sites on RB18A protein. RB18A mutants (lanes 1 to 5) or GST (lane 6) were incubated with double-stranded DNA-cellulose in presence of 100 mM NaCl. Bound proteins were eluted, run on a 10% SDS ± PAGE and transferred to nitrocellulose sheets. Detection was performed using an anti-GST Ab. Position of molecular marker size is indicated on the right of the gel. (e) Schematic representation of the localization of the RB18A functional domains. The domain responsible for the activation of p53 speci®c DNA binding function was characterized in Figure 8 1993; Kim et al., 1996) , as p53. Therefore, Kim et al. (1996) suggested that the common structural epitope recognized by PAb421 Moab could imply a functional homology between RAD50 and p53. Thus, PAb421 moAb could de®ne a motif in a protein family, including RB18A, RAD50 and p53, which carried DNA-binding and oligomerization domains. Demonstration that a moAb may de®ne a functionally conserved epitope on two distinct proteins has been also suggested for PAb204, an anti-T-Ag moAb. Indeed, PAb204 reacted with T-Ag and with a p68 protein (Lane and Hoeer, 1980) , both proteins exhibiting RNA helicase activity (Ford et al., 1988; Hirling et al., 1989) .
Furthermore, RB18A regulated p53 speci®c binding on his DNA consensus binding site. While the exact mechanism of p53 and RB18A interaction remains unknown, absence of detectable amount of RB18A protein in the retarded band suggested that the activation of p53 binding on DNA by RB18A was induced through an unstable (and/or low anity) interaction between both proteins. The unstable interaction of RB18A with p53 which activated its binding to DNA was similar to the unstable interaction of p53 C-terminal domain added in trans which activated the p53 binding to his cognate DNA binding site (Jayaraman and Prives, 1995) . However, a stable (and/or higher anity) interaction between GST-RB18A and wild-type or mutated p53 was shown in absence of speci®c p53 DNA binding sequence. Hupp et al. (1995) suggested that interaction of the Cterminal domain of one p53 molecule with distinct region of other p53 molecule locks p53 in an inactive form for DNA binding. Addition in trans of a Cterminal peptide could promote the dissociation of the C-terminal of the full length p53 from the other region of p53. Disruption of this inhibitory interaction would induce the conformational change required to activate the DNA binding of p53. Thus, RB18A could play the same role by interacting with p53, therefore promoting conformational change of p53 and demasking its sequence-speci®c DNA binding domain.
Altogether, these data demonstrated that RB18A protein, which carried common antigenic and functional properties with p53, is a new protein which could regulate p53 functions.
Materials and methods
Cell culture
Raji Burkitt B lymphoma cells were grown at 378C in RPMI 1640 medium supplemented with 10% (v/v) heatinactivated FCS in presence of 5% CO 2 . Step II
Step I p53 Figure 9 The C-terminal domain of RB18A protein activates the p53 DNA binding in synergy with PAb421 moAb, in a dosedependent manner. Two ml of in vitro translated products of wildtype p53 were incubated for 20 min at room temperature in the ®rst step either with 50 ng of PAb421 moAb (lanes 1 ± 5) or increasing amounts of GST-RB18A-N2 protein (200 ng, 400 ng or 1 mg, lanes 6, 7 or 8 respectively) or with 1mg GST-RB18A-NI1 (lane 9). Then, in a second step, either increasing amounts of GST-RB18A-N2 (200 ng, 400 ng or 1 mg, lanes 2, 3 or 4 respectively) or 1 mg GST-RB18A-NI1 (lane 5) or 50 ng of Pab421 moAb (lanes 6 to 9) were added for 20 min at room temperature. Then, speci®c labeled p53 oligonucleotide was added in every lane for 20 min at 48C. Complexes were run on a 4% acrylamide gel in 0.46TBE buer. Positions of free DNA and speci®c complex are indicated
Antibodies
Monoclonal anti-p53 antibodies (moAbs) PAb1801 (aa 46-55), PAb421 (aa 371-380) and DO-1 (aa 21-25) were purchased from Oncogene Science. Other anti-p53 moAbs HO7-1 (aa 291-300), and HO15-4 (aa 86-95) (Legros et al., 1994) were kindly provided by T Soussi (Institut Curie, Paris, France). Polyclonal anti-peptide p53.1 and anti-RB18A antibodies were prepared by immunizing two rabbits every 2 weeks with 0.6 mg of synthetic peptide (aa 13-27 of the human p53, PLSQETFSDLWKLLP) covalently coupled to KLH (Pierce) or 30 mg of GST-RB18A-N1 fusion protein, respectively, in presence of Freund complete adjuvant for the ®rst two immunizations and of Freund incomplete adjuvant for the last two immunizations. Rabbits were bled ten days after the last immunization and presence of speci®c antibodies in the sera was tested on Raji cell extracts by Western blot.
Isolation of RB18A cDNA
A UniZAP-XR cDNA library was constructed from 5 mg polyadenylated RNA (Sambrook et al., 1989) using the ZAPcDNA synthesis kit (Stratagene). The library contained a total of 2.10 6 pfu/ml and was ampli®ed to a titer of 3.10 9 pfu/ ml. Screening of 6.10 5 pfu was performed with PAb1801 moAb (0.2 mg/ml) in buer containing 20 mM Tris, pH 7.5, 150 mM NaCl and 1% BSA. Goat anti-mouse Ab coupled to alkaline phosphatase (Dako) was used as the detection system for positive plaques and developed with BCIP/NBT reagents (Sigma). One clone (D9) containing the partial open reading frame of RB18A was retained. For the obtention of full-length RB18A cDNA, a 32 P-labelled probe generated from the 5' end of D9 cDNA was used to screen a lgt11 human heart cDNA library (6.10 5 pfu) purchased from Clontech. A set of overlapping cDNAs was obtained. Sequencing was made in both directions using the T7 Sequenase polymerase sequencing kit (Amersham) with speci®c sequence primers.
Plasmids and constructions
The plasmid pSP65-p53H8 encodes for the human wild-type p53 cDNA (Harris et al., 1986) (kindly provided by V Rotter, Weizmann Institute of Science, Rehovot, Israel), while the plasmid to pGEM4-T1388 encodes a human p53 mutant with proline at position 273 (kindly provided by J Milner, University of York, York, England).
The GST-RB18A-N1 (aa 436 to 1566) fusion protein was obtained by cloning the D9 cDNA downstream of the glutathione transferase gene into the pGEX4T-3 vector (Pharmacia LKB). GST-RB18A-N2 (aa 1234 to 1566) was obtained by deleting the 5'-sequence of D9 cDNA up to a BamHI (nt 3938) restriction site. A GST-RB18A-NI1 fusion protein, deleted in N-terminal and in central part of the protein, was obtained by digesting D9 cDNA with PstI restriction enzyme. The resulting protein is composed from amino acids 436 to 927 fusioned in frame with amino acids 1537 to 1566. Other fusion proteins were constructed using PCR fragments subcloned into the BamHI and EcoRI restriction sites of pGEX4T-3 vector. The GST-RB18A-NC1 (aa 436 to 1228) fusion protein was obtained using 5' primer 5'-AGGGATCCG-TATCTTTTCAGCACCCTG TG-3' (nt 1544) and 3' primer 5'-AGGAATTCTCACTTCATGCCAGAGCTTGAACT-3' (nt 3921) and the GST-RB18A-NC2 (aa 1234 to 1406) fusion protein using 5' primer 5'-CAGTAATAGTACTCTCTCGG-3' (nt 3938) and 3' primer 5'-AGGAATTCTAAGCCCTTCTC-CACTACTT-3' (nt 4934).
In vitro transcription/translation and immunoprecipitation
Transcription and translation were performed with the TNT-coupled reticulocyte lysate system (Promega) in presence of 35 S-methionine (Amersham) according to the manufacturer's instructions. For immunoprecipitation procedure, translation product (5 ml) was incubated for 90 min at 48C in 20 mM Tris (pH 7.4), 150 mM NaCl, 5 mM EDTA and 0.5% NP40 with 1 mg of the dierent moAbs bound to 15 ml protein G plus/protein A agarose (Oncogene Science) or with 50 ml rabbit sera bound to 10 mg Protein A sepharose (Pharmacia). Then, immunobeads were extensively washed. Bound proteins were eluted in sample buer by heating for 3 min at 1008C and analysed by 10% SDS ± PAGE (Laemmli, 1970) Western immunoblotting b-galactosidase fusion proteins were overproduced in transformed XL1-blue bacteria cells after a 3 h induction by 10 mM IPTG. Pelleted cells were boiled for 3 min in Laemmli sample buer and proteins were analysed on 10% SDS ± PAGE. Immunoblotting was performed using different moAb or polyclonal Ab followed with peroxidase labeled secondary Ab, as previously described (Barel, 1991) .
Northern blot analysis
A blot containing 5 mg polyadenylated RNA from a variety of human tissues was purchased from Clontech and hybridized with the 800 bp probe derived from the 5' end of D9 cDNA.
GST-fusion-protein anity chromatography
GST fusion proteins were produced in E. coli strain BL21 and puri®ed on glutathione Sepharose 4B beads (Pharmacia LKB) as described by the manufacturer. Equal amount (1 mg) of GST-RB18A fusion proteins or GST alone bound to beads were incubated with 35 S-radiolabeled translated products for 1 h at 48C in buer containing 50 mM Tris (pH 7.1), 150 mM NaCl, 1 mM EDTA, and 1% NP40. After washing, pelleting, and boiling in Laemmli buer, eluted proteins were resolved on 10% SDS ± PAGE and visualized by autoradiography.
DNA-binding assay
DNA-binding assays of 35 S-translated products (3 ml) or GST-fusion proteins (1 mg) were performed as previously described (Kern et al., 1991) except that GST-fusion proteins were detected by immunoblotting using a polyclonal anti-GST Ab diluted 1/500 (Oncogene Science).
Electrophoretic Mobility Shift Assay (EMSA)
The oligonucleotide containing the 20-mer p53 consensus DNA binding site and EcoRI-compatible ends 5'-AATT-CAGACATGCCTAGACATGCCTG-3' (Funk et al., 1992) was synthesized, hybridized with the complementary oligonucleotide and end-labeled with [
32 P]g-ATP as described (Sambrook et al., 1989 ). An oligonucleotide (TL; Hupp et al., 1992) , 5'-TATGTCTAAGGGA CCTGCGGTTGGCATTGATCTTG-3', which did not contain the consensus sequence was prepared in doublestranded form and used as non-speci®c competitor.
EMSA was performed as follows. Translated product (4 ml) was pre-incubated for 20 min at room temperature with 1 mg of GST-RB18A fusion protein or 0.2 mg of moAb in a ®nal reaction volume of 14 ml of buer A (25 mM Tris, pH 7.4, 80 mM KCl, 0.1 nM EDTA, 1 mM DTT and 10% glycerol). Then, 6 ml of buer B (80 mM KCI, 16.6 mM MgCl 2 and 3 mg/ ml BSA) containing 0.4 ng of labeled oligonucleotide and 0.5 mg of poly(dI-dC) were added and incubation was carried out for 20 min at 48C. Reaction products were run for 15 min at 200 V on a 4% polyacrylamide gel containing 0.46Tris-Borate-EDTA (90 mM Tris, 64.6 mM Borate, 2.5 mM EDTA, pH 8.3).
